Keya Zhang

Dr. Keya Zhang is the Executive Director of Corporate Strategy and Business Development at Sansure Biotech, Inc., a leading IVD company in China. At Sansure Biotech, Keya leads a cross-functional team of scientists, medical specialists, and commercial experts to formulate concrete, actionable corporate strategies and R&D roadmaps. He also is responsible for Sansure’s investment, M&A, and licensing activities, and has played a critical role in its investment in, and strategic collaboration with, innovative IVD companies such as QuantuMDx, Genemind, Singlera, and First Light Diagnostics.

Prior to joining Sansure, Keya served as Director of Corporate Strategy at Genscript, where he worked on a wide range of commercial and R&D projects spanning synthetic biology, cell and gene therapy, as well as antibody drugs. He also previously worked as a Research Scientist at DuPont in the field of industrial enzymes, synthetic biology and gene editing. Keya obtained his Ph.D. in Chemistry at the University of Chicago.